游离DNA对骨髓增生异常综合征的分子与细胞遗传学特征分析
本研究对70例骨髓增生异常综合征(MDS)患者进行游离DNA(cfDNA)二代测序,并与配对骨髓DNA测序比较。cfDNA与骨髓DNA突变谱一致率为92.1%,变异等位基因频率(VAF)强相关,SF3B1突变在cfDNA中VAF显著更高;cfDNA可检测骨髓中NGS发现的全部细胞遗传学异常,并在治疗应答者中VAF下降,2例无应答者显示细胞遗传学演化。
要点
- cfDNA与骨髓DNA突变谱一致率为92.1%,VAF强相关。
- SF3B1突变在cfDNA中VAF显著高于骨髓DNA。
- cfDNA可检测骨髓NGS发现的全部细胞遗传学异常。
核心结论
- cfDNA分析是MDS分子特征分析、染色体异常检测和监测的有前景策略,但需更大队列的进一步研究。
研究设计与样本
- 对70例MDS患者队列进行cfDNA二代测序(NGS),并与配对骨髓DNA测序比较。
主要发现
- 骨髓DNA与cfDNA测序突变谱一致率为92.1%,两者VAF强相关。
- SF3B1突变在cfDNA中VAF显著高于骨髓DNA。
- NGS与微阵列检测染色体改变高度一致,但灵敏度低于核型和荧光原位杂交。
- 骨髓DNA中NGS检测到的全部细胞遗传学异常均在cfDNA中检测到。
- 在多个配对时间点,骨髓DNA与cfDNA突变VAF相关性极好;治疗应答者cfDNA VAF下降,无应答者未下降,2例无应答者cfDNA显示细胞遗传学演化。
关键数值与推荐
- 骨髓DNA与cfDNA突变谱一致率为92.1%。
- SF3B1突变在cfDNA中VAF显著高于骨髓DNA。
- NGS与微阵列检测染色体改变高度一致,但灵敏度低于核型和荧光原位杂交。
临床怎么用
- 原文未据此给出推荐。
局限性
- 需更大队列的进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Molecular and cytogenetic studies are essential for diagnosis and prognosis in patients with myelodysplastic syndromes (MDSs). Cell-free DNA (cfDNA) analysis has been reported to be a reliable noninvasive approach for detecting molecular abnormalities in MDS; however, there is limited information about cytogenetic alterations and monitoring in cfDNA. We assessed the molecular and cytogenetic profile of a cohort of 70 patients with MDS by next-generation sequencing (NGS) of cfDNA and compared the results to sequencing of paired bone marrow (BM) DNA. Sequencing of BM DNA and cfDNA showed a comparable mutational profile (92.1% concordance), and variant allele frequencies (VAFs) strongly correlated between both sample types. Of note, SF3B1 mutations were detected with significantly higher VAFs in cfDNA than in BM DNA. NGS and microarrays were highly concordant in detecting chromosomal alterations although with lower sensitivity than karyotype and fluorescence in situ hybridization. Nevertheless, all cytogenetic aberrations detected by NGS in BM DNA were also detected in cfDNA. In addition, we monitored molecular and cytogenetic alterations and observed an excellent correlation between the VAFs of mutations in BM DNA and cfDNA across multiple matched time points. A decrease in the cfDNA VAFs was detected in patients responding to therapy, but not in nonresponding patients. Of note, cfDNA analysis also showed cytogenetic evolution in 2 nonresponsive cases. In summary, although further studies with larger cohorts are needed, our results support the analysis of cfDNA as a promising strategy for performing molecular characterization, detection of chromosomal aberrations and monitoring of patients with MDS.
引用
- Garcia-Gisbert N, Garcia-Ávila S, Merchán B, et al. Molecular and cytogenetic characterization of myelodysplastic syndromes in cell-free DNA. Blood Adv. 2022. PMID: 35192693. doi:10.1182/bloodadvances.2021006565
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。